Announcement • Jun 03
iCoreConnect Inc. Filed for Bankruptcy iCoreConnect Inc., along with its one affiliate, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Middle District of Florida on June 2, 2025. The debtor listed both its assets and liabilities in the range of $1 million to $10 million. The debtor is represented by Amy Denton Mayer of Stichter Riedel Blain & Postler, P.A. as its legal counsel. Announcement • May 16
iCoreConnect Inc. announced delayed 10-Q filing On 05/15/2025, iCoreConnect Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Apr 28
Nasdaq Grants Extension to iCoreConnect to Regain Compliance with Listing Rules As previously disclosed, iCoreConnect Inc. was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that it was not in compliance with: (i) the minimum stockholders’ equity requirement for continued listing set forth in Listing Rule 5550(b)(1); (ii) Listing Rule 5250(b)(1) due to the Company’s failure to promptly disclose the information in its Form 8-K dated March 26, 2025; (iii) Listing Rule 5250(a)(1) due to its failure to include the disclosure in its Form 8-K dated March 26, 2025, in its hearing submission to the Nasdaq Hearings Panel (“Panel”), which was submitted on March 14, 2025; and (iv) Listing Rule 5250(c)(1) since it had not yet filed its Form 10-K for the period ended December 31, 2024. The Company requested a hearing, which had the effect of staying any suspension or delisting action pending the conclusion of the hearings process. On April 24, 2025, the Company received notification from the Panel that it has granted an extension until May 15, 2025 to file its Form 10-K for the period ended December 31, 2024, and until June 30, 2025, to demonstrate compliance with all continued listing requirements for the Nasdaq Capital Market. The notification received by the Company also served as a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D) due to the Company’s failure to promptly disclose the information in its Form 8-K dated March 26, 2025 pursuant to Listing Rule 5250(b)(1) and due to its failure to include the disclosure in its Form 8-K dated March 26, 2025, in its hearing submission to the Panel pursuant to Listing Rule 5250(a)(1). The Public Reprimand Letter closes the violation of Listing Rule 5250(b)(1) and Listing Rule 5250(a)(1). Announcement • Apr 22
iCoreConnect Inc. Provides Non-Compliance Update On April 16, 2025, iCoreConnect Inc. (the Company") received a letter (the Letter") from the staff of the Listing Qualifications Department (the Staff") of The Nasdaq Stock Market LLC (Nasdaq"), which notified the Company that since it had not yet filed its Form 10-K for the period ended December 31, 2024, it no longer complied with Nasdaq Listing Rule 5250(c)(1) for continued listing. The Staff indicated that this matter would serve as an additional basis for delisting the Company's securities. The Staff advised the Company that the Nasdaq Hearings Panel (Panel") that heard the Company's submission will consider this matter in their decision regarding the Company's continued listing on The Nasdaq Capital Market and that the Company should present its views with respect to this additional deficiency to the Panel in writing no later than April 23, 2025. Announcement • Apr 14
Icoreconnect Inc. Announces Board and Committee Changes, Effective April 10, 2025 On April 10, 2025, Kevin McDermott resigned from his position as member of iCoreConnect Inc.’s board of directors effective on such date. Mr. McDermott’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. On April 10, 2025, Adam Chambers, Angel Liriano, David Piedra and Joseph Tung were appointed to the Board of Directors of the Company. Upon such appointment, the Board committees are as follows: (i) the Company’s Audit Committee shall be Wayne Kalish, John Pasqual and Angel Liriano, (ii) the Company’s Compensation Committee shall be Wayne Kalish, John Pasqual and David Piedra, and (iii) the Company’s Nominating and Governance Committee shall be Wayne Kalish, John Pasqual and Joseph Tung. Announcement • Apr 08
iCoreConnect Receives Non-Compliance Letter from Nasdaq Regarding Listing Rule 5250(b)(1) On April 1, 2025, iCoreConnect Inc. (the ‘Company’) received a letter (the ‘Letter’) from the staff of the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’), which notified the Company that it had violated Listing Rule 5250(b)(1) due to the Company’s failure to promptly disclose the information in its Form 8-K dated March 26, 2025. In addition, the Staff determined that the Company had violated Listing Rule 5250(a)(1) due to its failure to include the disclosure in its Form 8-K dated March 26, 2025, in its hearing submission to the Nasdaq Hearings Panel (‘Panel’), which was submitted on March 14, 2025. The Staff indicated that these matters would serve as an additional and separate basis for delisting and instructed the Company to present its views with the respect to these deficiencies at its Panel hearing, which occurred on April 3, 2025. On March 26, 2025, the Company filed a Form 8-K stating that on March 10, 2025, it had received notice from PIGI Solutions, LLC (‘PIGI’) that PIGI was exercising its purported right as a secured creditor under the Uniform Commercial Code (Del. UCC § 9-613) to conduct a public auction of substantially all of the Company’s personal property. PIGI has indicated that the closing of the auction is to occur on or after May 9, 2025. PIGI claims the Company owes $2,434,243 in principal and interest. The amounts arise out of finder’s fee agreement discussed below. The Company stated in such Form 8-K that it disputes the alleged indebtedness and PIGI’s right to conduct an auction of its assets. On April 4, 2025, the Company and its wholly-owned subsidiary, iCore Midco Inc. (‘Midco’) filed a complaint in the United States District Court Middle District of Florida initiating a civil action against PIGI and John Schneller (the ‘Defendants’). In the complaint, the Company and Midco assert, among other claims, that the Defendants fraudulently induced Midco into a finder’s fee agreement, under which PIGI acted as an unregistered broker-dealer, and that the finder’s fee agreement is voidable under Section 29(b) of the Securities Exchange Act of 1934. The relief requested includes, among other things, rescission of the finder’s fee agreement and related loan documents, injunctive relief against PIGI taking any further action to enforce the finder’s fee agreement, and monetary damages. Also on April 4, 2025, along with the complaint, the Company and Midco filed an emergency motion for a temporary restraining order and for a preliminary injunction to enjoin PIGI from conducting the auction. Announcement • Apr 01
iCoreConnect Inc. announced delayed annual 10-K filing On 03/31/2025, iCoreConnect Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Feb 23
Nasdaq to Suspend Trading in iCoreConnect Common Stock Effective February 27 As previously reported, on August 20, 2024, iCoreConnect Inc. (the Company") received a deficiency letter from the Listing Qualifications Department (the Staff") of the Nasdaq Stock Market (Nasdaq") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing set in Nasdaq Listing Rule 5550(b) (the Equity Rule"). The Company was provided an initial period that ended on February 17, 2025 to regain compliance with the Equity Rule, and, as of such date, the Company was not in compliance with the Equity Rule. On February 18, 2025, the Company was notified by the Staff that unless the Company requests an appeal of the Staff's determination by February 25, 2025, trading of the Company's common stock will be suspended at the opening of business on February 27, 2025, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. The Company plans to timely submit a hearing request to Nasdaq's Hearings Panel, which will stay the suspension of the Company's common stock and the filing of the Form 25-NSE pending the Panel's decision. Announcement • Nov 15
iCoreConnect Inc. announced delayed 10-Q filing On 11/14/2024, iCoreConnect Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Sep 12
iCoreConnect Inc. Announces the Appointment of Yvonne Hyland to its Board of Directors iCoreConnect Inc. has announced the appointment of Yvonne Hyland to its Board of Directors. With over 30 years of experience in the global technology industry, Yvonne Hyland has held leadership positions in both startups and Fortune 100 companies. Her impressive career includes key roles at SAP and Gartner, as well as founding and scaling several technology product and service companies, culminating in successful exits. In addition to her entrepreneurial endeavors, Ms. Hyland has also served as a venture capital operator. She attended the MBA program at the Martin J. Whitman School of Management and is currently a Syracuse University Libraries Advisory Board member. Announcement • Aug 22
iCoreConnect Receives Non-Compliance Letter from Nasdaq Regarding Listing Rule 5550(b)(1) On August 20, 2024, iCoreConnect Inc. (the Company") received a letter (the Letter") from the staff of the Listing Qualifications Department (the Staff") of The Nasdaq Stock Market LLC (Nasdaq"), which notified the Company that it does not presently comply with Nasdaq's Listing Rule 5550(b)(1) (the Listing Rule"), which requires that the Company maintain a minimum of $2.5 million in stockholders' equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set in the Listing Rule. The Letter does not have any immediate effect on the listing of the Company's common stock on the Nasdaq Capital Market, and the Company has 45 calendar days to submit a plan to regain compliance. If the Company's plan is accepted, the Staff can grant an extension of up to 180 calendar days from August 20, 2024 to evidence compliance. After review of the plan of compliance, the Staff will provide written notification to the Company whether it accepts the plan, and if the Staff does not accept the plan, the Company would then be entitled to appeal the Staff's determination to the Nasdaq Hearings Panel. There can be no assurance that, if the Company does appeal the determination to the Nasdaq Hearings Panel, that such appeal would be successful. Announcement • Aug 16
iCoreConnect Inc. announced delayed 10-Q filing On 08/15/2024, iCoreConnect Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Aug 12
iCoreConnect Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Listing Rules 5605(b)(1)(A) and 5605(c)(4) On August 7, 2024, iCoreConnect Inc., (the Company") was notified by the Listing Qualifications Department (the Staff") of the Nasdaq Stock Market (Nasdaq") that, following the resignation of Harry Travis from the Company's board of directors (the Board") on June 30, 2024, the Company does not have a Board comprised of a majority of independent directors, an audit committee comprised of three independent directors and a compensation committee comprised of at least two independent directors. Therefore, the Company is no longer eligible for a cure period for majority board independence and audit committee composition as contemplated under Listing Rules 5605(b)(1)(A) and 5605(c)(4). Under the Listing Rules, the Company has 45 calendar days to submit a plan to regain compliance. If the Company's plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from August 7, 2024 to evidence compliance. Announcement • Jul 12
iCoreConnect Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market On July 8, 2024, iCoreConnect Inc. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that for the last 32 consecutive business days the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until January 6, 2025, to regain compliance with the Bid Price Rule. If, at any time before the Compliance Date, the closing bid price for the Company’s common stock closes at $1.00 or more for a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Rule, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company is not in compliance with the Bid Price Rule by January 6, 2025, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the minimum bid price deficiency, which may include, if necessary, implementing a reverse stock split. If the Company does not regain compliance with the Bid Price Rule by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock may be delisted. The Company would then be entitled to appeal the Staff’s determination to a NASDAQ Listing Qualifications Panel and request a hearing. There can be no assurance that, if the Company does appeal the delisting determination by the Staff to the NASDAQ Listing Qualifications Panel, that such appeal would be successful. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, which could include effecting a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule. Announcement • May 11
iCoreConnect Inc. Receives Non-Compliance Notice from the Nasdaq Stock Market LLC On May 6, 2024, Joseph Gitto, a member of the board of directors (the Board") of iCoreConnect Inc. (the Company") resigned from his position as member of the Board, including as a member of the audit committee of the Board (the Audit Committee"). Such resignation was effective immediately. On May 8, 2024, the Company received a written notice (the Notice") from The Nasdaq Stock Market LLC (Nasdaq"), indicating that, as a result of Mr. Gitto's resignation from the Board and Audit Committee, the Company is not currently in compliance with Nasdaq Listing Rule 5605, which requires that (i) a majority of the Board be comprised of independent directors and (ii) the Audit Committee is comprised of at least three independent directors. The Company currently has four directors, only two of which qualify as independent directors. In addition, the Audit Committee currently is comprised of only two independent directors. In accordance with Nasdaq Listing Rule 5605(b)(1)(A) and 5605(c)(4), the Company has a cure period" of until the earlier of the Company's next annual shareholders' meeting or May 6, 2025, or if the next annual shareholders' meeting is held before November 4, 2024, then the Company must evidence compliance no later than November 4, 2024. The Company intends to elect one or more independent directors to serve as a member of the Board and the Audit Committee during this cure period. The Notice has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market. Announcement • May 09
iCoreConnect Inc. Announces the Resignation of Joseph Gitto as Member of the Board of Directors On May 6, 2024, Joseph Gitto, a member of the board of directors of iCoreConnect Inc. resigned from his position as member of the Board. Such resignation was effective immediately. Announcement • Apr 02
iCoreConnect Inc. announced delayed annual 10-K filing On 04/01/2024, iCoreConnect Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Feb 01
iCoreConnect Inc. Announces Latest Version of iCoreCodeGenius iCoreConnect Inc. announced its latest version of iCoreCodeGenius. iCoreConnect announced significant enhancements to its iCoreCodeGenius Software as a Service (SaaS) offering. iCoreCodeGenius delivers fast, reliable, and accurate medical coding to provide healthcare organizations with the appropriate codes and documentation needed, resulting in reduced claim denials. The latest update was tailor-made with the needs of healthcare professionals in mind, and will provide them with even more powerful tools and features to streamline their workflows, boost productivity, and drive business growth. Key features and improvements in the updated iCoreCodeGenius include: Advanced Coding: Enhanced capabilities provide users with deeper insights into their data and help them make more informed decisions with the addition of CPT code lookups. Enhanced User Interface: The revamped user interface offers a sleek, intuitive design, making it easier than ever for users to navigate the platform and access the features they need. Enhanced Integration Options: The updated solution now offers seamless integration with even more third-party EHR/EMR and Practice Management software, facilitating greater connectivity across users' tech ecosystems. Improved Performance: Optimizations to the solution's backend enhance speed and reliability, ensuring a more efficient workflow. Enhanced Security: Recognizing the critical importance of data security, the updated iCoreCode Genius includes the latest security features to protect sensitive information. Scalability: As business grows, iCoreConnect grows with you. Scalability has been a core focus to ensure, enabling users to adapt the solution to their changing needs. Announcement • Dec 19
Icoreconnect, Inc. Announces the Launch of Fintech Software Solution icorepay iCoreConnect Inc. announced the launch of iCorePay, a Fintech software solution with best-in-class features, technologies, and integrations for healthcare payment and billing processes. iCorePay brings a comprehensive suite of features to the market designed to revolutionize the healthcare payment and billing experience. iCorePay, a cloud-based solution, aims to redefine how healthcare practices manage and streamline their payment and billing processes by providing unprecedented adaptability, seamless integration, and convenience. iCorePay introduces a singular, comprehensive platform that seamlessly encompasses every aspect of the patient payment journey. Key features of the iCorePay platform include: Best in Class Digital Patient Billing: digital patient billing system sets a new standard in the industry. It offers a user-friendly interface, detailed billing information, and real-time updates, thereby improving transparency and trust between healthcare practices and their patients. iCorePay ensures patient statements are securely and compliantly delivered across both online and offline channels. Patients can receive statements digitally on their devices, or via a practice-branded paper statement embedded with a QR code. This approach guarantees a true omnichannel experience in patient billing, blending convenience with security. This ensures that healthcare practices can accommodate the diverse payment preferences of their patients, enhancing patient satisfaction and streamlining transaction processes. Pay Over Time Solutions: In a bid to make healthcare more accessible, iCorePay incorporates third-party patient financing and automated recurring in-practice payment plans, allowing patients to pay over time. Not only does this ease the financial burden on patients, but also improves cash flow for practices. Membership Program Functionality: iCorePay introduces an innovative membership program functionality, designed to support practices in offering subscription-based healthcare services. This feature creates new potential revenue streams for practices and provides patients with more options for their healthcare needs. Fully Self-Service Purchase and Onboarding: In a significant move towards user independence, iCorePay offers the option for full self-service software purchasing and onboarding process for new practice customers. This feature allows practices to easily acquire and implement the iCorePay solution, streamlining the setup process. iCorePay also offers iCoreConnect's renowned customer success services for practices who prefer a guided onboarding approach. Innovative Mobile Payment Terminal Device: iCorePay includes a mobile payment terminal experience for in-practice payments. This device brings iCorePay's powerful software functionality to the palm of hand, enabling on-the-go payment processing that enhances the convenience for both healthcare providers and patients. Announcement • Nov 17
iCoreConnect Inc. announced delayed 10-Q filing On 11/15/2023, iCoreConnect Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Aug 26
iCoreConnect Inc. Provides Revenue Guidance for the Fiscal Year 2023 iCoreConnect Inc. provided revenue guidance for the fiscal year 2023. For the year, the company's continues to expect to achieve its previously stated fiscal year 2023 revenue forecast of approximately $17 million with annualized recurring revenue (ARR) at the end of 2023 of approximately $29 million (calculated as December 2023 revenue multiplied by twelve).